BIO-Europe Spring® 2017: Commercializing cell and gene therapies

April 4, 2017

New business models for clinical development and manufacturing require strategic partnerships among researchers, manufacturers and payers to fully realize the commercial opportunities.

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Article
VIDEO: Innovation in an uncertain world
VIDEO: Innovation in an uncertain world

How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price an...

Next Video
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its...